Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P11230

UPID:
ACHB_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P11230; B7Z5H1; Q8IZ46; Q96FB8

BACKGROUND:
Acetylcholine receptor subunit beta, with the unique identifier P11230, is crucial for the activation of ion channels in response to acetylcholine, facilitating communication across the neuromuscular junction. This process is essential for muscle contraction and overall motor function.

THERAPEUTIC SIGNIFICANCE:
Disruptions in the function of this protein are linked to congenital myasthenic syndromes, including CMS2A, a slow-channel syndrome, and CMS2C, associated with acetylcholine receptor deficiency. Targeting the Acetylcholine receptor subunit beta offers a promising avenue for developing treatments for these debilitating conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.